Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Identifieur interne : 001946 ( Main/Exploration ); précédent : 001945; suivant : 001947Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Auteurs : Ivorie Coleman [États-Unis] ; Gabriel Ruiz [États-Unis] ; Sumir Brahmbhatt [États-Unis] ; Lindsay Ackerman [États-Unis]Source :
- Journal of medical case reports [ 1752-1947 ] ; 2020.
Descripteurs français
- KwdFr :
- Antipaludiques (administration et posologie), Antipaludiques (effets indésirables), Biopsie (méthodes), Facteurs immunologiques (MeSH), Femelle (MeSH), Humains (MeSH), Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Immunoglobulines par voie veineuse (administration et posologie), Infections à coronavirus (épidémiologie), Maladies de la peau (traitement médicamenteux), Méthylprednisolone (administration et posologie), Pandémies (MeSH), Peau (anatomopathologie), Pneumopathie virale (épidémiologie), Pustulose exanthématique aigüe généralisée (diagnostic), Pustulose exanthématique aigüe généralisée (physiopathologie), Pustulose exanthématique aigüe généralisée (thérapie), Pustulose exanthématique aigüe généralisée (étiologie), Résultat thérapeutique (MeSH), Sarcoïdose (traitement médicamenteux), Sujet âgé (MeSH), Syndrome de Stevens-Johnson (diagnostic), Syndrome de Stevens-Johnson (physiopathologie), Syndrome de Stevens-Johnson (thérapie), Syndrome de Stevens-Johnson (étiologie).
- MESH :
- administration et posologie : Antipaludiques, Hydroxychloroquine, Immunoglobulines par voie veineuse, Méthylprednisolone.
- anatomopathologie : Peau.
- diagnostic : Pustulose exanthématique aigüe généralisée, Syndrome de Stevens-Johnson.
- effets indésirables : Antipaludiques, Hydroxychloroquine.
- méthodes : Biopsie.
- physiopathologie : Pustulose exanthématique aigüe généralisée, Syndrome de Stevens-Johnson.
- thérapie : Pustulose exanthématique aigüe généralisée, Syndrome de Stevens-Johnson.
- traitement médicamenteux : Maladies de la peau, Sarcoïdose.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- étiologie : Pustulose exanthématique aigüe généralisée, Syndrome de Stevens-Johnson.
- Facteurs immunologiques, Femelle, Humains, Pandémies, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Acute Generalized Exanthematous Pustulosis (diagnosis), Acute Generalized Exanthematous Pustulosis (etiology), Acute Generalized Exanthematous Pustulosis (physiopathology), Acute Generalized Exanthematous Pustulosis (therapy), Aged (MeSH), Antimalarials (administration & dosage), Antimalarials (adverse effects), Biopsy (methods), COVID-19 (MeSH), Coronavirus Infections (epidemiology), Female (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Immunoglobulins, Intravenous (administration & dosage), Immunologic Factors (MeSH), Methylprednisolone (administration & dosage), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Sarcoidosis (drug therapy), Skin (pathology), Skin Diseases (drug therapy), Stevens-Johnson Syndrome (diagnosis), Stevens-Johnson Syndrome (etiology), Stevens-Johnson Syndrome (physiopathology), Stevens-Johnson Syndrome (therapy), Treatment Outcome (MeSH).
- MESH :
- chemical , administration & dosage : Antimalarials, Hydroxychloroquine, Immunoglobulins, Intravenous, Methylprednisolone.
- chemical , adverse effects : Antimalarials, Hydroxychloroquine.
- diagnosis : Acute Generalized Exanthematous Pustulosis, Stevens-Johnson Syndrome.
- drug therapy : Sarcoidosis, Skin Diseases.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- etiology : Acute Generalized Exanthematous Pustulosis, Stevens-Johnson Syndrome.
- methods : Biopsy.
- pathology : Skin.
- physiopathology : Acute Generalized Exanthematous Pustulosis, Stevens-Johnson Syndrome.
- therapy : Acute Generalized Exanthematous Pustulosis, Stevens-Johnson Syndrome.
- Aged, COVID-19, Female, Humans, Immunologic Factors, Pandemics, Treatment Outcome.
Abstract
BACKGROUND
Since the World Health Organization declared a global pandemic due to the novel coronavirus disease2019, there have been targeted efforts to establish management modalities. Hydroxychloroquine has been suggested as a possible treatment; however, it is associated with multiple adverse reactions. We report a rare case of a patient with acute generalized exanthematous pustulosis with Stevens-Johnson syndrome due to hydroxychloroquine. Acute generalized exanthematous pustulosis is characterized by acute onset of a generalized rash that is pustular and erosive in nature, affecting limbs; trunk; face; and, less often, mucosal membranes. Although rare, it is important to be mindful of this side effect because the diagnosis is often delayed, and the disease has the potential to be life-threatening.
CASE PRESENTATION
A 68-year-old American woman presented to our hospital with a painful, rapidly spreading rash. Its morphologic features included erythema multiforme-like lesions with extensive skin sloughing in various regions of the head, neck, and trunk and mucosal involvement. Her Nikolsky sign was negative, and she had no evidence of lesions on areas of skin trauma. Four weeks prior, she had been initiated on hydroxychloroquine for a presumed diagnosis of cutaneous sarcoidosis. Three punch biopsies of the head and neck area revealed subcorneal pustules consistent with acute generalized exanthematous pustulosis. Treatment began with high doses of methylprednisolone, leading to only minimal improvement of existing areas and ongoing spread to new areas. Treatment with intravenous immunoglobulin was initiated, at which point disease stability was achieved. The patient's rash ultimately resolved, as did her cutaneous pain and pruritus.
CONCLUSIONS
Among many potential adverse reactions involving hydroxychloroquine, cutaneous side effects are varied and can lead to significant morbidity or even death. The drug is currently being investigated in a multitude of trials for coronavirus disease2019 treatment, prevention, and prophylaxis after exposure to severe acute respiratory syndrome coronavirus 2. Acute generalized exanthematous pustulosis is a rare side effect of hydroxychloroquine, and even fewer cases demonstrate histologic evidence of acute generalized exanthematous pustulosis while clinically presenting with Stevens-Johnson syndrome. Patients who develop Stevens-Johnson syndrome/toxic epidermal necrolysis require best supportive care with aggressive fluid and electrolyte replacement and prevention of further breakdown of the skin barrier. With the potential of widespread hydroxychloroquine use, it is important that providers be aware of its potential severe adverse drug reactions.
DOI: 10.1186/s13256-020-02504-8
PubMed: 33138853
PubMed Central: PMC7605900
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.</title>
<author><name sortKey="Coleman, Ivorie" sort="Coleman, Ivorie" uniqKey="Coleman I" first="Ivorie" last="Coleman">Ivorie Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA. ivorie.coleman@bannerhealth.com.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ruiz, Gabriel" sort="Ruiz, Gabriel" uniqKey="Ruiz G" first="Gabriel" last="Ruiz">Gabriel Ruiz</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brahmbhatt, Sumir" sort="Brahmbhatt, Sumir" uniqKey="Brahmbhatt S" first="Sumir" last="Brahmbhatt">Sumir Brahmbhatt</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ackerman, Lindsay" sort="Ackerman, Lindsay" uniqKey="Ackerman L" first="Lindsay" last="Ackerman">Lindsay Ackerman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Banner University Medical Center - Phoenix Division of Dermatology, University of Arizona College of Medicine, Phoenix, 475 North 5th Street, Phoenix, AZ, 85004, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Banner University Medical Center - Phoenix Division of Dermatology, University of Arizona College of Medicine, Phoenix, 475 North 5th Street, Phoenix, AZ, 85004</wicri:regionArea>
<wicri:noRegion>85004</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33138853</idno>
<idno type="pmid">33138853</idno>
<idno type="doi">10.1186/s13256-020-02504-8</idno>
<idno type="pmc">PMC7605900</idno>
<idno type="wicri:Area/Main/Corpus">000899</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000899</idno>
<idno type="wicri:Area/Main/Curation">000899</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000899</idno>
<idno type="wicri:Area/Main/Exploration">000899</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.</title>
<author><name sortKey="Coleman, Ivorie" sort="Coleman, Ivorie" uniqKey="Coleman I" first="Ivorie" last="Coleman">Ivorie Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA. ivorie.coleman@bannerhealth.com.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ruiz, Gabriel" sort="Ruiz, Gabriel" uniqKey="Ruiz G" first="Gabriel" last="Ruiz">Gabriel Ruiz</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brahmbhatt, Sumir" sort="Brahmbhatt, Sumir" uniqKey="Brahmbhatt S" first="Sumir" last="Brahmbhatt">Sumir Brahmbhatt</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ackerman, Lindsay" sort="Ackerman, Lindsay" uniqKey="Ackerman L" first="Lindsay" last="Ackerman">Lindsay Ackerman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ</wicri:regionArea>
<placeName><region type="state">Arizona</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Banner University Medical Center - Phoenix Division of Dermatology, University of Arizona College of Medicine, Phoenix, 475 North 5th Street, Phoenix, AZ, 85004, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Banner University Medical Center - Phoenix Division of Dermatology, University of Arizona College of Medicine, Phoenix, 475 North 5th Street, Phoenix, AZ, 85004</wicri:regionArea>
<wicri:noRegion>85004</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of medical case reports</title>
<idno type="eISSN">1752-1947</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Generalized Exanthematous Pustulosis (diagnosis)</term>
<term>Acute Generalized Exanthematous Pustulosis (etiology)</term>
<term>Acute Generalized Exanthematous Pustulosis (physiopathology)</term>
<term>Acute Generalized Exanthematous Pustulosis (therapy)</term>
<term>Aged (MeSH)</term>
<term>Antimalarials (administration & dosage)</term>
<term>Antimalarials (adverse effects)</term>
<term>Biopsy (methods)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Immunoglobulins, Intravenous (administration & dosage)</term>
<term>Immunologic Factors (MeSH)</term>
<term>Methylprednisolone (administration & dosage)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Sarcoidosis (drug therapy)</term>
<term>Skin (pathology)</term>
<term>Skin Diseases (drug therapy)</term>
<term>Stevens-Johnson Syndrome (diagnosis)</term>
<term>Stevens-Johnson Syndrome (etiology)</term>
<term>Stevens-Johnson Syndrome (physiopathology)</term>
<term>Stevens-Johnson Syndrome (therapy)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antipaludiques (administration et posologie)</term>
<term>Antipaludiques (effets indésirables)</term>
<term>Biopsie (méthodes)</term>
<term>Facteurs immunologiques (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Immunoglobulines par voie veineuse (administration et posologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Maladies de la peau (traitement médicamenteux)</term>
<term>Méthylprednisolone (administration et posologie)</term>
<term>Pandémies (MeSH)</term>
<term>Peau (anatomopathologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Pustulose exanthématique aigüe généralisée (diagnostic)</term>
<term>Pustulose exanthématique aigüe généralisée (physiopathologie)</term>
<term>Pustulose exanthématique aigüe généralisée (thérapie)</term>
<term>Pustulose exanthématique aigüe généralisée (étiologie)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sarcoïdose (traitement médicamenteux)</term>
<term>Sujet âgé (MeSH)</term>
<term>Syndrome de Stevens-Johnson (diagnostic)</term>
<term>Syndrome de Stevens-Johnson (physiopathologie)</term>
<term>Syndrome de Stevens-Johnson (thérapie)</term>
<term>Syndrome de Stevens-Johnson (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimalarials</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulins, Intravenous</term>
<term>Methylprednisolone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimalarials</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antipaludiques</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulines par voie veineuse</term>
<term>Méthylprednisolone</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Peau</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Acute Generalized Exanthematous Pustulosis</term>
<term>Stevens-Johnson Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Pustulose exanthématique aigüe généralisée</term>
<term>Syndrome de Stevens-Johnson</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoidosis</term>
<term>Skin Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antipaludiques</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Acute Generalized Exanthematous Pustulosis</term>
<term>Stevens-Johnson Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biopsy</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Biopsie</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Skin</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Pustulose exanthématique aigüe généralisée</term>
<term>Syndrome de Stevens-Johnson</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Acute Generalized Exanthematous Pustulosis</term>
<term>Stevens-Johnson Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Acute Generalized Exanthematous Pustulosis</term>
<term>Stevens-Johnson Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Pustulose exanthématique aigüe généralisée</term>
<term>Syndrome de Stevens-Johnson</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies de la peau</term>
<term>Sarcoïdose</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Pustulose exanthématique aigüe généralisée</term>
<term>Syndrome de Stevens-Johnson</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>COVID-19</term>
<term>Female</term>
<term>Humans</term>
<term>Immunologic Factors</term>
<term>Pandemics</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Facteurs immunologiques</term>
<term>Femelle</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Since the World Health Organization declared a global pandemic due to the novel coronavirus disease2019, there have been targeted efforts to establish management modalities. Hydroxychloroquine has been suggested as a possible treatment; however, it is associated with multiple adverse reactions. We report a rare case of a patient with acute generalized exanthematous pustulosis with Stevens-Johnson syndrome due to hydroxychloroquine. Acute generalized exanthematous pustulosis is characterized by acute onset of a generalized rash that is pustular and erosive in nature, affecting limbs; trunk; face; and, less often, mucosal membranes. Although rare, it is important to be mindful of this side effect because the diagnosis is often delayed, and the disease has the potential to be life-threatening.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CASE PRESENTATION</b>
</p>
<p>A 68-year-old American woman presented to our hospital with a painful, rapidly spreading rash. Its morphologic features included erythema multiforme-like lesions with extensive skin sloughing in various regions of the head, neck, and trunk and mucosal involvement. Her Nikolsky sign was negative, and she had no evidence of lesions on areas of skin trauma. Four weeks prior, she had been initiated on hydroxychloroquine for a presumed diagnosis of cutaneous sarcoidosis. Three punch biopsies of the head and neck area revealed subcorneal pustules consistent with acute generalized exanthematous pustulosis. Treatment began with high doses of methylprednisolone, leading to only minimal improvement of existing areas and ongoing spread to new areas. Treatment with intravenous immunoglobulin was initiated, at which point disease stability was achieved. The patient's rash ultimately resolved, as did her cutaneous pain and pruritus.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Among many potential adverse reactions involving hydroxychloroquine, cutaneous side effects are varied and can lead to significant morbidity or even death. The drug is currently being investigated in a multitude of trials for coronavirus disease2019 treatment, prevention, and prophylaxis after exposure to severe acute respiratory syndrome coronavirus 2. Acute generalized exanthematous pustulosis is a rare side effect of hydroxychloroquine, and even fewer cases demonstrate histologic evidence of acute generalized exanthematous pustulosis while clinically presenting with Stevens-Johnson syndrome. Patients who develop Stevens-Johnson syndrome/toxic epidermal necrolysis require best supportive care with aggressive fluid and electrolyte replacement and prevention of further breakdown of the skin barrier. With the potential of widespread hydroxychloroquine use, it is important that providers be aware of its potential severe adverse drug reactions.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33138853</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>1</Issue>
<PubDate><Year>2020</Year>
<Month>Nov</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Journal of medical case reports</Title>
<ISOAbbreviation>J Med Case Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.</ArticleTitle>
<Pagination><MedlinePgn>210</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-020-02504-8</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since the World Health Organization declared a global pandemic due to the novel coronavirus disease2019, there have been targeted efforts to establish management modalities. Hydroxychloroquine has been suggested as a possible treatment; however, it is associated with multiple adverse reactions. We report a rare case of a patient with acute generalized exanthematous pustulosis with Stevens-Johnson syndrome due to hydroxychloroquine. Acute generalized exanthematous pustulosis is characterized by acute onset of a generalized rash that is pustular and erosive in nature, affecting limbs; trunk; face; and, less often, mucosal membranes. Although rare, it is important to be mindful of this side effect because the diagnosis is often delayed, and the disease has the potential to be life-threatening.</AbstractText>
<AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 68-year-old American woman presented to our hospital with a painful, rapidly spreading rash. Its morphologic features included erythema multiforme-like lesions with extensive skin sloughing in various regions of the head, neck, and trunk and mucosal involvement. Her Nikolsky sign was negative, and she had no evidence of lesions on areas of skin trauma. Four weeks prior, she had been initiated on hydroxychloroquine for a presumed diagnosis of cutaneous sarcoidosis. Three punch biopsies of the head and neck area revealed subcorneal pustules consistent with acute generalized exanthematous pustulosis. Treatment began with high doses of methylprednisolone, leading to only minimal improvement of existing areas and ongoing spread to new areas. Treatment with intravenous immunoglobulin was initiated, at which point disease stability was achieved. The patient's rash ultimately resolved, as did her cutaneous pain and pruritus.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among many potential adverse reactions involving hydroxychloroquine, cutaneous side effects are varied and can lead to significant morbidity or even death. The drug is currently being investigated in a multitude of trials for coronavirus disease2019 treatment, prevention, and prophylaxis after exposure to severe acute respiratory syndrome coronavirus 2. Acute generalized exanthematous pustulosis is a rare side effect of hydroxychloroquine, and even fewer cases demonstrate histologic evidence of acute generalized exanthematous pustulosis while clinically presenting with Stevens-Johnson syndrome. Patients who develop Stevens-Johnson syndrome/toxic epidermal necrolysis require best supportive care with aggressive fluid and electrolyte replacement and prevention of further breakdown of the skin barrier. With the potential of widespread hydroxychloroquine use, it is important that providers be aware of its potential severe adverse drug reactions.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coleman</LastName>
<ForeName>Ivorie</ForeName>
<Initials>I</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-1407-3732</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA. ivorie.coleman@bannerhealth.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ruiz</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brahmbhatt</LastName>
<ForeName>Sumir</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ackerman</LastName>
<ForeName>Lindsay</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Banner University Medical Center - Phoenix Division of Dermatology, University of Arizona College of Medicine, Phoenix, 475 North 5th Street, Phoenix, AZ, 85004, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>11</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Med Case Rep</MedlineTA>
<NlmUniqueID>101293382</NlmUniqueID>
<ISSNLinking>1752-1947</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber>
<NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D056150" MajorTopicYN="Y">Acute Generalized Exanthematous Pustulosis</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013262" MajorTopicYN="Y">Stevens-Johnson Syndrome</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AGEP</Keyword>
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Case report</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>11</Month>
<Day>3</Day>
<Hour>5</Hour>
<Minute>33</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33138853</ArticleId>
<ArticleId IdType="doi">10.1186/s13256-020-02504-8</ArticleId>
<ArticleId IdType="pii">10.1186/s13256-020-02504-8</ArticleId>
<ArticleId IdType="pmc">PMC7605900</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cutis. 2016 Mar;97(3):212-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27023083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2016 Aug 9;134(6):e32-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27400984</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Dermatol. 2007 Nov;157(5):989-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17854366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Inflamm Res. 2018 Mar 28;11:135-142</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29636627</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2016 Jul 27;17(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27472323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Case Rep. 2018 Oct 26;6(12):2391-2395</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30564334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Clin North Am. 2010 Jul;94(4):727-42, x</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20609860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inflammopharmacology. 2015 Oct;23(5):231-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26246395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32070753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105945</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 1998 Mar 14;351(9105):771</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9519945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Burn Care Res. 2008 Nov-Dec;29(6):1004-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18849840</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Arizona</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Arizona"><name sortKey="Coleman, Ivorie" sort="Coleman, Ivorie" uniqKey="Coleman I" first="Ivorie" last="Coleman">Ivorie Coleman</name>
</region>
<name sortKey="Ackerman, Lindsay" sort="Ackerman, Lindsay" uniqKey="Ackerman L" first="Lindsay" last="Ackerman">Lindsay Ackerman</name>
<name sortKey="Ackerman, Lindsay" sort="Ackerman, Lindsay" uniqKey="Ackerman L" first="Lindsay" last="Ackerman">Lindsay Ackerman</name>
<name sortKey="Brahmbhatt, Sumir" sort="Brahmbhatt, Sumir" uniqKey="Brahmbhatt S" first="Sumir" last="Brahmbhatt">Sumir Brahmbhatt</name>
<name sortKey="Ruiz, Gabriel" sort="Ruiz, Gabriel" uniqKey="Ruiz G" first="Gabriel" last="Ruiz">Gabriel Ruiz</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001946 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001946 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:33138853 |texte= Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33138853" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |